Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland
STOCKHOLM, 22 August 2018 -- Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, announces today that The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland has approved the company’s application to start a Phase IIb study (HEAL) with LL-37 for treatment of venous leg ulcers.Promore Pharma’s phase IIb study with LL-37, HEAL (A Study in Patients with Hard-to-Heal Venous Leg Ulcers to Measure Efficacy and Safety of Locally Administered LL-37) is anticipated to recruit 120 patients with venous leg ulcers (VLU) in Sweden